New and updated preclinical and clinical data presented by biopharma firms at the Society for Immunotherapy of Cancer’s annual meeting Nov. 9-14, including: 4D, Acepodia, Advaxis, Affimed, Agenus, Alkermes, Alx, Amgen, Beam, Bioinvent, Checkpoint, Codiak, Genocea, Huya, Kleo, Oncolytics, Oncosec, Rubius, Transgene, Vigeo, Windmil.
New updates from a dynamic late-phase systemic lupus erythematosus pipeline shared at this week's American College of Rheumatology annual meeting and beyond showed a robust field of potential new treatments nearing the finish line.
An earlier-than-intended release of abstracts for the American Society of Hematology annual meeting spilled multiple market-moving updates Nov. 4, though with no apparent shocks so far. Shares of Allogene Therapeutics Inc. sunk 8% on Nov. 4 over some metered disappointment around initial data for ALLO-715, a potential medicine for relapsed/refractory (r/r) multiple myeloma. By contrast, shares of Global Blood Therapeutics Inc. climbed nearly 15%, buoyed by new data supporting the long-term use of its sickle cell disease therapy, Oxbryta (voxelotor).
DUBLIN – The global product development pipeline for COVID-19 is now twice as big as for any particular cancer indication, a major disease like Alzheimer’s or any other infectious disease indication.
CYBERSPACE – “We are not very good at predicting drug response in the clinic,” Ayesha Muhammad told the audience at the 2020 annual meeting of the American Society of Human Genetics (ASHG), “though it is not for lack of trying.” Nevertheless, adverse drug reactions are among the top 10 causes of in-hospital mortality.
DUBLIN – The biotechnology sector may be more awash with cash now than at any other time in its history. But that does not alter the fundamental dynamic between biotech and big pharma. If anything, their respective roles are becoming better defined, as biotechs learn how to build value into their assets to the point where big pharma is willing to step in and take on the financial risk of scaling a program where it can truly go global.
The opening plenary abstract session at the 2020 annual meeting of the American Society of Human Genetics (ASHG) began with the definition of a new disease, identified through a new approach, and possibly leading to a new way to think about rheumatic diseases.
DUBLIN – The dateline says it all. Everyone and anyone with an interest in European biotechnology were due to assemble in Munich this week, the German biotech hub which was originally chosen to host Bio-Europe Fall 2020. Given the rising numbers of confirmed COVID-19 cases across the globe in recent months, that was never going to happen.
Under the right circumstances, a single mouse can be as good as a group of eight or 10 animals in predicting whether a tumor will respond to a drug, researchers reported at the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting on Saturday. The single-animal approach “allows incorporation of more tumor models within the same resource constraints,” Peter Houghton told reporters at a press conference previewing ENA highlights.
New and updated preclinical and clinical data presented by biopharma firms at the 32nd EORTC-NCI-AACR Symposium, including: Aileron, Basilea, Black Diamond, Cyclacel, Elevation Oncology, Essa, Exelixis, Kura, Medicenna, Mirati, Rain, Revolution, Syros.
RSS
